Definium Therapeutics Us, Inc.
Clinical trials sponsored by Definium Therapeutics Us, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a modified MDMA ease autism symptoms? small trial begins Results expected Aug 2027 (estimated)
- Could a Psychedelic-Like pill beat depression? phase 3 trial underway Results expected Sep 2027 (estimated)
-
Could a modified MDMA ease autism symptoms? small trial begins
Symptom relief Recruiting nowThis study tests a drug called DT402 (a form of MDMA) in 20 adults with autism spectrum disorder. The goal is to see if it can reduce the severity of social and communication problems. Participants will take the drug and report their experiences using simple rating scales. It is …
Phase 2 • Sponsor: Definium Therapeutics US, Inc. • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Could a Psychedelic-Like pill beat depression? phase 3 trial underway
Symptom relief Recruiting nowThis phase 3 study is testing an oral drug called DT120 (related to LSD) against a placebo in 165 adults with major depressive disorder. Participants will take the drug or placebo for 12 weeks, followed by a 40-week period where everyone can receive DT120. The main goal is to see…
Phase 3 • Sponsor: Definium Therapeutics US, Inc. • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC